Novo Nordisk A/S (NYSE:NVO) saw unusually-strong trading volume on Monday . Approximately 4,235,029 shares changed hands during mid-day trading, an increase of 43% from the previous session’s volume of 2,964,876 shares.The stock last traded at $46.81 and had previously closed at $46.18.

A number of brokerages have recently weighed in on NVO. Bank of America Corp. cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, August 8th. Zacks Investment Research cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Monday, July 4th. Goldman Sachs Group Inc. cut Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, June 28th. Finally, Citigroup Inc. restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Wednesday, August 3rd. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $61.00.

The company has a market capitalization of $118.19 billion and a PE ratio of 22.14. The company has a 50 day moving average price of $53.44 and a 200-day moving average price of $53.97.

The business also recently disclosed a dividend, which will be paid on Tuesday, August 23rd. Investors of record on Monday, August 15th will be paid a dividend of $0.326 per share. The ex-dividend date of this dividend is Thursday, August 11th.

An institutional investor recently raised its position in Novo Nordisk A/S stock. Bank of Montreal Can increased its position in Novo Nordisk A/S (NYSE:NVO) by 16.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 64,142 shares of the company’s stock after buying an additional 8,892 shares during the period. Bank of Montreal Can’s holdings in Novo Nordisk A/S were worth $3,726,000 as of its most recent filing with the SEC.

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.